Oslo biotech finds another merger partner after shareholders rejected November offer

09 Jun 2023

Acquisition

Shareholders of Nordic Nanovector Nanovector did not like the first merger partner the Norwegian biotech chose last fall. So the company went back to the drawing board and has found a new one: Thor Medical. Nordic Nanovector had originally planned to combine with APIM Therapeutics , but a few weeks after the November disclosure, shareholders decided it was a no-go. This time around, Nordic Nanovector hopes to combine with the small, private Thor Medical, which is working on proprietary tech to make radionuclides, including alpha-particle emitters that it plans to supply to radiopharma companies for cancer therapeutics. By its count, more than 50 such startups and biopharma companies are working on cancer radiotherapy, and it expects to make a final decision on an industrial-scale manufacturing facility in 2025.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Nordic Nanovector ASA

Thor Medical AS

APIM Therapeutics AS

Indications

Neoplasms

Targets

Drugs

NV.RYM.01

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.